AR126834A1 - PSILOCINE PRODRUGS AND DERIVATIVES AND USES OF THESE - Google Patents
PSILOCINE PRODRUGS AND DERIVATIVES AND USES OF THESEInfo
- Publication number
- AR126834A1 AR126834A1 ARP220102243A ARP220102243A AR126834A1 AR 126834 A1 AR126834 A1 AR 126834A1 AR P220102243 A ARP220102243 A AR P220102243A AR P220102243 A ARP220102243 A AR P220102243A AR 126834 A1 AR126834 A1 AR 126834A1
- Authority
- AR
- Argentina
- Prior art keywords
- psilocine
- prodrugs
- derivatives
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- SPCIYGNTAMCTRO-UHFFFAOYSA-N psilocin Chemical compound C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 title 2
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto caracterizado porque es de fórmula (1) o una sal o sal, solvato o isotopólogo farmacéuticamente aceptable de este. Un compuesto caracterizado porque es de la fórmula (2), o una sal, solvato o isotopólogo farmacéuticamente aceptable de este. Una composición farmacéutica caracterizada porque comprende un compuesto según una cualquiera de las reivindicaciones 1 a 180, o una sal farmacéuticamente aceptable de este, y un excipiente o transportador farmacéuticamente aceptable.A compound characterized in that it is of formula (1) or a pharmaceutically acceptable salt, solvate or isotopologue thereof. A compound characterized in that it is of formula (2), or a pharmaceutically acceptable salt, solvate or isotopologue thereof. A pharmaceutical composition characterized in that it comprises a compound according to any one of claims 1 to 180, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063289025P | 2020-12-13 | 2020-12-13 | |
| US202163235543P | 2021-08-20 | 2021-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126834A1 true AR126834A1 (en) | 2023-11-22 |
Family
ID=89061586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102243A AR126834A1 (en) | 2020-12-13 | 2022-08-19 | PSILOCINE PRODRUGS AND DERIVATIVES AND USES OF THESE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126834A1 (en) |
-
2022
- 2022-08-19 AR ARP220102243A patent/AR126834A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001367A2 (en) | Antiviral compounds | |
| AR128931A1 (en) | COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF | |
| AR132338A1 (en) | RAS INHIBITORS | |
| AR131639A1 (en) | KIF18A INHIBITORS AND THEIR USES | |
| CO2021014210A2 (en) | Pyrrole compounds | |
| CO2023002940A2 (en) | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | |
| PE20251667A1 (en) | Cyclic thiazolyl urea compounds for the treatment of HSV | |
| AR128066A1 (en) | HETEROCYCLIC PYRIMIDINE COMPOUND AND METHOD OF PREPARATION AND MEDICAL USE THEREOF | |
| DOP2025000009A (en) | NOVEL ACC INHIBITORS | |
| AR126834A1 (en) | PSILOCINE PRODRUGS AND DERIVATIVES AND USES OF THESE | |
| CL2025001119A1 (en) | Cancer treatment methods using isoquinoline or 6-aza-quinoline derivatives | |
| AR130303A1 (en) | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | |
| AR132838A1 (en) | PRMT5 INHIBITORS AND THEIR USES | |
| AR132166A1 (en) | NLRP3 INFLAMMASOME INHIBITORS AND THEIR USES | |
| AR132905A1 (en) | Selective bifunctional degraders of SMARCA2 and their therapeutic uses | |
| AR128693A1 (en) | ANTIVIRAL COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | |
| AR130602A1 (en) | TEAD INHIBITORS AND METHODS OF USE THEREOF | |
| AR130979A1 (en) | HETEROCYL COMPOUNDS AND THEIR USES | |
| AR128780A1 (en) | NLRP3 MODULATORS | |
| AR131850A1 (en) | LACTAM-SUBSTITUTED IMIDAZOTRIAZINE IL-17A MODULATORS AND THEIR USES | |
| AR133855A1 (en) | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | |
| AR124982A1 (en) | MACROCYCLES AND THEIR USES | |
| AR128896A1 (en) | IKZF2 DEGRADERS AND USES OF THESE | |
| AR131906A1 (en) | THERAPEUTIC COMPOUNDS | |
| AR133489A1 (en) | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |